---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-006831"
form_type: "8-K"
ticker: "ACTU"
cik: "0001652935"
company_name: "ACTUATE THERAPEUTICS, INC."
filed_at: "2025-09-10T23:59:59+00:00"
generated_at: "2026-05-17T07:01:49.232832+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Actuate Therapeutics prices $15M public offering of 2.14M shares at $7.00/share

## Summary
- Offers 2,142,858 shares at $7.00/share; gross proceeds ~$15M before discounts and expenses.
- Underwriters granted 30-day over-allotment option for up to 321,428 additional shares.
- Closing expected September 11, 2025; proceeds for working capital and general corporate purposes.
- Directors and executive officers subject to lock-up until December 9, 2025.
- Lucid Capital Markets sole book-runner; Titan Partners Group as financial advisor.

## SEC filing metadata
- accession: 0001683168-25-006831
- form_type: 8-K
- ticker: ACTU
- cik: 0001652935
- company_name: ACTUATE THERAPEUTICS, INC.
- filed_at: 2025-09-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652935/000168316825006831/0001683168-25-006831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652935/000168316825006831/actuate_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-006831
- JSON: https://secwatch.observer/filing/0001683168-25-006831.json
- Plain text: https://secwatch.observer/filing/0001683168-25-006831.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.